Crown, J. (2025) “TCHL – a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis”, Acta Oncologica, 64, pp. 751–760. doi: 10.2340/1651-226X.2025.43143.